PATENT

## THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of	)
Evan C. Unger et al.	) Confirmation No.: 5427
Serial No. 10/802,919	) Group Art Unit: 1616
Filed: March 18, 2004	) Examiner: TBD
For: METHODS FOR DELIVERING COMPOUNDS INTO A CELL.	) ) Attv. Dkt. No. 006086,00020

### REQUEST FOR CORRECTED FILING RECEIPT

U.S. Patent and Trademark Office Customer Service Window Randolph Building 401 Dulany Street Alexandria, VA 22314

Dear Sir:

It is requested that a corrected Filing Receipt be issued to include information not listed on the Official Filing Receipt. Specifically, the following should be added after the last line in the Domestic Priority data: "which is a CON of 08/346,426 11/29/94 PAT 5,733,572".

A copy of the Official Filing Receipt with the correction marked in red is attached.

Should the U.S. Patent and Trademark Office determine a fee is required, please charge such fee to our Deposit Account No. 19-0733.

Respectfully submitted,

Sarah A. Kagan

Registration No. 32,141

BANNER & WITCOFF, LTD. 1001 G Street, N.W., 11<sup>th</sup> Floor Washington, D.C. 20001 (202) 824-3000

Dated: March 18, 2005

JNITED STATES PA MAR 1 8 2005

i and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPL NO.

FILING OR (CADITICAL) (c) DATE

FIL FEE REC'D 385

ATTY.DOCKET NO

DRAWINGS

IND CLMS

10/802.919 03/18/2004

006086.00020

TOT CLMS

22907 **BANNER & WITCOFF** 1001 G STREET N W **SUITE 1100** WASHINGTON, DC 20001

**CONFIRMATION NO. 5427** FILING RECEIPT

\*OC000000012827821

Date Mailed: 06/01/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Evan C. Unger, Tucson, AZ; Thomas McCreery, Tucson, AZ;

**Assignment For Published Patent Application** 

ImaRx Pharmaceutical Corp., Tucson, AZ;

Domestic Priority data as claimed by applicant

This application is a DIV of 08/841,169 04/29/1997 PAT 6,743,779 which is a CIP of 08/785,661 01/17/1997 ABN which is a CIP of 08/640,554 05/01/1996 ABN

which is a CON of 08/346,426 11/29/1994 PAT 5,733,572 0060 86.00020

**Foreign Applications** 

**RECEIVED** 

If Required, Foreign Filing License Granted: 05/31/2004

**BANNER & WITCOFF** 

Non-Publication Request: No

Projected Publication Date: 09/09/2004

hevid own

Early Publication Request: No

\*\* SMALL ENTITY \*\*







**Title** 

Methods for delivering compounds into a cell

Preliminary Class

424

# LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

#### **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).